NCT00195364已完成不适用
Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 93 人开始时间: 2003年7月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 93
研究概览
简要总结
The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To have completed 0881A1-301-EU study in Spain
- •Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.
排除标准
- •Hypersensibility to etanercept or any of its components
- •Significant concurrent medical disease
研究者
相似试验
已完成
不适用
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics RegistryRheumatoid ArthritisNCT01646385Pfizer6,393
已完成
不适用
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in SpainArthritis, PsoriaticArthritis, RheumatoidNCT00195377Wyeth is now a wholly owned subsidiary of Pfizer1,000
已完成
3 期
16.0040 Ankylosing Spondylitis StudyAnkylosing SpondylitisNCT00356356Amgen257
已完成
3 期
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing SpondylitisAnkylosing SpondylitisNCT00421980Wyeth is now a wholly owned subsidiary of Pfizer84
已完成
4 期
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic TreatmentsPsoriasisNCT00967538Innovaderm Research Inc.89